Seeking Alpha

Royalty Pharma offers to purchase Elan (ELN) for $11/share in cash, saying it contacted Elan...

Royalty Pharma offers to purchase Elan (ELN) for $11/share in cash, saying it contacted Elan before Friday's deal with Biogen. Royalty believes its offer allows shareholders to cash out without facing the "substantial" execution risks associated with the in-licensing deal for Tysabri. Shares +8.1% to $11.46 premarket. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)